Brief: Lumiradx Continues Commercial Expansion Of Its Rapid Microfluidic Immunoassay HbA1c Test
14/11/2022 08:03
Nov 14 (Reuters) - LumiraDx Ltd LMDX.O :
* LUMIRADX CONTINUES COMMERCIAL EXPANSION OF ITS RAPID
MICROFLUIDIC IMMUNOASSAY HBA1C TEST
* LUMIRADX EXPANDING HBA1C TEST IN EUROPE, PARTS OF THE
MIDDLE
EAST, ASIA, LATIN AMERICA, AND AFRICA
Source text for Eikon: ID:nGNE18gmQZ
Further company coverage: LMDX.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing